Senolytics: The Drugs That Clear Ageing Cells and What That Means for Longevity

The Cells That Refuse to Leave

In biology, death is not always the enemy. Cells that have been damaged beyond repair are supposed to die cleanly through a process called apoptosis, a form of controlled self-destruction that allows the body to clear debris and replace worn-out cells with new ones. This process is essential for healthy tissue maintenance. But there is another fate available to damaged cells, and it is considerably messier: senescence.

A senescent cell is one that has stopped dividing permanently but has also stopped dying. It sits in the tissue in a kind of cellular limbo, neither functioning normally nor clearing out of the way. Worse, it starts secreting a cocktail of inflammatory signals, enzymes, and growth factors that researchers have collectively named the senescence-associated secretory phenotype, or SASP. The SASP is essentially a biological distress signal that, when emitted chronically by accumulating numbers of senescent cells across multiple tissues, becomes a significant driver of age-related disease and decline.

The discovery that you could identify what makes senescent cells resist death, and then design drugs to exploit those survival mechanisms, gave birth to the field of senolytics. It is one of the most exciting areas in longevity research today, with real clinical trials producing encouraging early data in humans.

Why Cells Become Senescent

Triggers and Protective Roles

Cellular senescence is not inherently pathological. In fact, it evolved as a tumor suppression mechanism. When a cell sustains damage that might push it toward uncontrolled proliferation, becoming cancer, senescence is one of the body's safeguards. By permanently halting the cell cycle, senescence prevents damaged cells from passing on mutations to daughter cells. Senescence also plays important roles in wound healing and embryonic development, where temporary senescent signals help coordinate tissue remodeling.

The triggers for senescence include DNA double-strand breaks (caused by radiation, oxidative stress, or replication errors), telomere shortening after repeated cell divisions, activation of oncogenes, and exposure to certain chemotherapy drugs. In young, healthy organisms, the immune system efficiently clears senescent cells after they have served their purpose. The problem arises with age: the immune system becomes less effective at surveillance and clearance, senescent cells accumulate in tissues, and the SASP transitions from a short-term signal to a chronic inflammatory burden.

The SASP: When a Good Signal Goes Bad

The components of the SASP include interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-alpha), matrix metalloproteinases, and dozens of other factors. In the short term, these signals recruit immune cells to clear the senescent cell and stimulate tissue repair. Chronically, they drive inflammaging, the low-grade systemic inflammation that underlies most of the major chronic diseases of ageing. SASP factors degrade the extracellular matrix that gives tissues their structural integrity, disrupt stem cell niches that are needed for tissue regeneration, and can even spread senescence to neighboring healthy cells in a process called paracrine senescence.

The Discovery of Senolytics

The key insight that led to senolytics came from asking a seemingly simple question: why do senescent cells not die? Normal apoptosis relies on a balance between pro-death proteins (like BAX and BAK) and anti-death proteins (like BCL-2 and BCL-XL). Researchers including James Kirkland and Tamara Tchkonia at the Mayo Clinic discovered that senescent cells upregulate a specific set of pro-survival pathways, particularly those involving BCL-2 family proteins, PI3K/AKT signaling, and other anti-apoptotic factors, to resist the very death signals that their own SASP should be triggering in neighboring cells.

In 2015, Kirkland and Tchkonia published a landmark paper in Cell that identified the first true senolytics: dasatinib, a tyrosine kinase inhibitor developed for leukemia, and quercetin, a flavonoid found in onions, apples, and capers. In cell culture and mouse models, the combination of dasatinib and quercetin (often abbreviated D+Q) selectively killed senescent cells while leaving non-senescent cells intact. Mice treated with D+Q showed reduced tissue senescent cell burden, lower SASP markers, improved physical function, and in some models, extended healthy lifespan. The paper generated enormous excitement precisely because it suggested that targeting senescent cells might be a practical strategy for treating age-related conditions in humans.

This connects directly to the broader framework of the hallmarks of ageing, where cellular senescence is identified as one of the primary drivers of the ageing process that cuts across virtually all age-related diseases.

The Clinical Trial Landscape

Pulmonary Fibrosis and Kidney Disease

Human clinical trials of senolytics began in earnest around 2018 and 2019, with Kirkland's group at the Mayo Clinic leading many of the early efforts. A small pilot trial in patients with idiopathic pulmonary fibrosis (IPF), a devastating lung disease driven heavily by senescent cell accumulation, treated 14 patients with three intermittent courses of D+Q over three weeks. The results, published in EBioMedicine in 2019, showed improvements in physical function metrics including six-minute walk distance, gait speed, chair-rise test, and short physical performance battery, alongside reductions in senescent cell markers in the lung and blood. While the trial was too small to be definitive, the functional improvements were striking.

A separate trial in patients with diabetic kidney disease found that a single three-day course of D+Q reduced senescent cell markers in adipose tissue biopsies and lowered plasma SASP factors including IL-6, MMP-2, and MMP-9. These findings established that senolytic drugs taken orally could reduce senescent cell burden in human tissue, which was an important validation of the basic hypothesis before investing in larger trials.

Navitoclax, Fisetin, and Next-Generation Agents

D+Q is not the only game in town. Navitoclax, a more potent BCL-2 family inhibitor developed for cancer, shows impressive senolytic activity in preclinical models but carries significant side effects including platelet reduction. Fisetin, another plant flavonoid found in strawberries, has shown senolytic activity in mouse models and is being studied in human trials for Alzheimer's disease prevention and frailty. ABT-263, another BCL-2 inhibitor, dramatically extended median and maximum lifespan in normal and radiation-induced prematurely aged mice. The race is on to find senolytics with better safety profiles and greater tissue specificity.

Senomorphics: A Complementary Strategy

Alongside senolytics, researchers are developing a related class of interventions called senomorphics. Rather than killing senescent cells outright, senomorphics suppress the SASP, reducing the inflammatory damage that senescent cells cause without eliminating the cells themselves. Rapamycin, the mTOR inhibitor discussed in its own article, shows senomorphic activity. Metformin also suppresses some SASP components. Certain natural compounds including resveratrol, curcumin, and spermidine have shown SASP-suppressing activity in cell culture, though human data remain limited.

The senomorphic approach may be preferable in some contexts: fully eliminating senescent cells has theoretical risks, particularly if those cells are playing ongoing roles in tissue homeostasis or wound healing. A combined strategy, using senomorphics chronically to reduce SASP burden and senolytics periodically to clear accumulated senescent cells, may represent the optimal approach, though this remains to be tested in humans.

The Road Ahead

The field of senolytic medicine is moving rapidly. Unity Biotechnology, one of the leading companies in the space, has run Phase 2 trials in ophthalmological conditions driven by senescent cells in the eye, including diabetic macular edema and age-related macular degeneration. Oisin Biotechnologies is developing gene therapy approaches that selectively kill cells based on their p16INK4a or p21 expression, markers of senescence, potentially offering much greater precision than small-molecule drugs.

The longevity implications of senolytics are potentially profound. If clearing senescent cells can improve function in multiple organ systems simultaneously, the concept of a "one disease at a time" approach to ageing medicine may give way to something more fundamental: treating the cellular ageing process itself. This aligns with growing interest in interventions like caloric restriction and mTOR signaling and oxidative stress and DNA damage that target ageing across multiple hallmarks simultaneously. The next decade of clinical trials will determine whether the extraordinary preclinical promise of senolytics translates into treatments that can meaningfully extend healthy human lifespan.